.Nature Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and overall survival, leading to FDA commendation as well as a brand-new therapy alternative for clients.